No Data
Delta-Fly Pharma to Start Phase 2/3 Trial of DFP-17729 for Pancreatic Cancer
March 25 [Today's Investment Strategy]
[Fisco Selected Stocks] 【Material Stocks】 Mimaki Engineering <6638> 1471 yen (3/24) Engaged in industrial inkjet printers, cutting plotters, etc. Announced a Financial Estimates of 25.0 yen for the ordinary dividends at the end of the fiscal year ending March 2025, plus a special dividend of 10.0 yen. The year-end dividend will be 35.0 yen (including a special dividend of 10.0 yen). The previous estimate was only an ordinary dividend of 15.0 yen, and the year-end dividend for the previous term was 15.0 yen. The annual dividend will be 52.5 yen.
The market is stable, supported by the rise in U.S. stocks, but resistance may be strong at higher levels.
[Emerging Markets Individual Stock Strategy] Today's Emerging Markets are expected to show a solid performance. On the US Stock Market yesterday, October 24, the Dow Inc rose significantly by 597.97 points (+1.42%) to 42,583.32 dollars. Reports suggested that the Trump administration's 'reciprocal tariffs' would be focused, and the unexpected rise in the March Services PMI supported stock prices. The buybacks in the high-tech sector continued, expanding the gain into the latter part of the day. Today's Emerging Markets are likely to experience a favorable buying trend.
＜Today's individual materials＞ Nakabotech, Creos, Bright Path, Nitto Kohki, ETC (announcements on the 24th)
▽ Nakabotec <1787.T> has revised its standalone financial estimates for the fiscal year ending March 2025 upward, raising its year-end total dividends estimate from 200 yen to 275 yen (previous fiscal year's figure was 240 yen). ▽ Creos <8101.T> has increased its year-end total dividends estimate for the fiscal year ending March 2025 from 90 yen to 95 yen (previous fiscal year's figure was 83 yen). ▽ Bright Pass <4594.T> has revised its standalone profit estimates downward for the fiscal year ending March 2025. ▽ Nitto Kohki <6151.T> has lowered its consolidated financial estimates for the fiscal year ending March 2025, and has adjusted its year-end dividends estimate accordingly.
Mirai Works, Cell Seed and others.
The acquisition of shares in Sky 365, which is involved in MSP (operations, monitoring, maintenance) business and Software Development related to Beex Cloud. <4594> Brightpath has revised its Financial Estimates, projecting an operating loss of 1.114 billion yen for this term, compared to 0.925 billion yen previously. <4598> A clinical phase 2/3 comparative trial of DELTA-PDFP-17729 has begun. <4881> A large exercise of the 12th subscription rights of Fanpepp with price adjustment clauses will start on the 17th, with the number of shares to be delivered being 85.
Key points of interest for PTS on the 24th = Maruha Nichiro, Daiko, Apirits.
▽ Maruha Nichiro <1333.T>, announcement of new long-term vision and medium-term management plan ▽ Daiko <3160.T>, Earnings Reports and revision of Financial Estimates ▽ Apirits <4174.T>, consolidated subsidiary acquires stocks of JUTJOY (becoming a subsidiary) ▽ BeeX <4270.T>, acquires Sky 365 as a subsidiary ▽ DeltaF <4598.T>, starts clinical phase 2/3 comparative trial for DFP-17729 ▽ Mimaki Engineering <6638.T>, revision of Dividends forecast ▽ Ikegami Tsusho <6771.T>, performance and Dividends.